TRIM15

Chr 6Multi

tripartite motif containing 15

Also known as: RNF93, ZNF178, ZNFB7

NCBI Gene: 89870ENSG00000204610UniProt: Q9C019

The protein encoded by this gene is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. The protein localizes to the cytoplasm. Alternatively spliced transcript variants have been described, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]

Primary Disease Associations & Inheritance

{Multiple sclerosis, susceptibility to, 1}MIM #126200
Multi
{Multiple sclerosis, susceptibility to, 1}MIM #126200
Multi
71
ClinVar variants
6
Pathogenic / LP
0.00
pLI score
0
Active trials
Clinical Summary— TRIM15
⚡
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
6 Pathogenic / Likely Pathogenic· 64 VUS of 71 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.30LOEUF
pLI 0.000
Z-score 0.63
OE 0.83 (0.55–1.30)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.41Z-score
OE missense 0.93 (0.84–1.03)
245 obs / 263.8 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.83 (0.55–1.30)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.93 (0.84–1.03)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.85
0≤1.21.6
LoF obs/exp: 14 / 16.8Missense obs/exp: 245 / 263.8Syn Z: 1.26

ClinVar Variant Classifications

71 submitted variants in ClinVar

ClinVar

Classification Summary

Pathogenic5
Likely Pathogenic1
VUS64
Likely Benign1
5
Pathogenic
1
Likely Pathogenic
64
VUS
1
Likely Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
5
0
5
Likely Pathogenic
0
0
1
0
1
VUS
0
62
2
0
64
Likely Benign
0
1
0
0
1
Benign
0
0
0
0
0
Total0638071

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

TRIM15 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM

{Multiple sclerosis, susceptibility to, 1}

MIM #126200

Molecular basis of disorder known

Multifactorial

{Multiple sclerosis, susceptibility to, 1}

MIM #126200

Molecular basis of disorder known

Multifactorial
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
TRIM15 drives chondrocyte senescence and osteoarthritis progression.
Li Z et al.·Sci Transl Med
2025
TRIM15 Exerts Anti-Tumor Effects Through Suppressing Cancer Cell Invasion in Gastric Adenocarcinoma.
Chen W et al.·Med Sci Monit
2018
High Expression of TRIM15 Is Associated with Tumor Invasion and Predicts Poor Prognosis in Patients with Gastric Cancer.
Zhou W et al.·J Invest Surg
2021Cohort
Telomere-related gene risk model for prognosis and drug treatment efficiency prediction in kidney cancer.
Li SC et al.·Front Immunol
2022Functional
Identification of a Two-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival in Diffuse-Type Gastric Cancer.
Chen S et al.·Curr Oncol
2022
Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients.
Lanata CM et al.·PLoS One
2018Clinical trial
Comprehensive analysis reveals common DNA methylation patterns of tobacco-associated cancers: A pan-cancer analysis.
Liu X et al.·Gene
2021
MYLK4 promotes colorectal cancer progression by regulating lipid metabolism reprogramming via targeting ferroptosis.
Wang B et al.·Neoplasia
2026
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →

External Resources

Links to major genomics databases and tools